Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

por O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Hu, James, Ganjoo, Kristen, Chow, Warren A., Do, Khanh T., Zlott, Jennifer, Bruns, Ashley, Rubinstein, Lawrence, Foster, Jared C., Juwara, Lamin, Meehan, Robert, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Takebe, Naoko, Voth, Andrea Regier, Bottaro, Donald, Costello, Rene, Wright, John J., Doroshow, James H., Chen, Alice P.
Publicado 2022